<DOC>
	<DOCNO>NCT02804217</DOCNO>
	<brief_summary>Patients advance non-small-cell lung cancer ( NSCLC ) harbor sensitive epithelial growth factor receptor ( EGFR ) mutation invariably develop acquire resistance EGFR tyrosine kinase inhibitor ( TKIs ) . Identification actionable genetic mutation helpful guide subsequent treatment . This study aim analyze genetic profile NSCLC harboring acquire resistance first-generation EGFR TKIs use next generation sequencing ( NGS ) .</brief_summary>
	<brief_title>Acquired Resistant Mechanism First-generation EGFR TKIs</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically proven stage IIIB IV nonsmall cell lung cancer patient harbor sensitive EGFR mutation receive firstgeneration EGFRTKIs develop acquire drug resistance patient provide pretreatment ( EGFR TKIs ) tumor tissue patient tumor lesion rebiopsy drug resistance patient must sign informed consent indicate aware .investigational nature study keep policy hospital . History another malignancy except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix patient systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>